Sai Life Sciences Limited - IPO

1. One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024, acting as a one-stop platform for discovery, development and manufacturing.

2. CDMO platform with a diverse mix of commercial and under-development molecules.

3. Fast-growing, integrated Discovery capabilities with focus on biology, chemistry and DMPK services.

4. Long-standing relationship with a diverse base of existing and new customers.

5. Modern R&D infrastructure with a differentiated delivery model and strong regulatory track-record.

6. Experienced management team and Board supported by a qualified scientific talent pool.

7. Strategic business investments with improving profitability metrics.

1. Its financial performance depends on the company's ability to secure business from biotechnology and pharmaceutical customers and consequently its may be subject to risks, uncertainties and trends that affect the company customers in these industries over which the company has no control.

2. Its business may be adversely affected by a failures to develop or manufacture commercially viable drugs, including for reasons that are not within the company control.

3. The company may not be able to continue to serve its customers if the company fails to meet their standards in audits and inspections and this could significantly harm its reputation and result in the termination of ongoing projects by its customers.

4. The company depends on its research and development activities generally for the company future growth and its inability to achieve the desired outcomes in the company research and development activities may result in customers opting to discontinue their partnerships with it.

5. The company is subject to extensive government regulation, and if the company fails to obtain, maintain or renew its statutory and regulatory licenses, permits and approvals required to operate the company's business, results of operations and cash flows may be adversely affected.

6. Manufacturing interruptions or delays could affect its ability to meet customer demand and lead to higher costs.

7. The company is subject to risks associated with conducting business internationally, and any operational delays and/or additional financial burdens may affect its business and results of operations.

8. The potential loss of major customers or any of its large contracts could materially and adversely affect the company's business, financial condition and results of operations.

9. The company conduct animal testing, which can result in adverse publicity liability and other issues, including potential disruption to its facilities as a result of protests against animal testing.

10. There have been instances in the past where the company has not made certain regulatory filings with the RoC or there were certain instances of discrepancies in relation to certain statutory filings and corporate records of the Company. Its cannot assure you that regulatory proceedings or actions will not be initiated against it in the future and the company will not be subject to any penalty imposed by the competent regulatory authority in this regard.